News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) Tumbles on Concerns About Generic Qsymia



8/20/2012 7:18:04 AM

Shares of Vivus Inc. stumbled Friday after an analyst slashed his sales estimates for Vivus' new obesity drug Qsymia, saying many physicians may prescribe Qsymia's ingredients for their patients instead of the drug itself. THE SPARK: Analyst Thomas Wei said he now believes a significant number of physicians will prescribe the two drugs that comprise Qsymia instead of giving their patients Qsymia itself, and that will cut into the drug's sales. Wei said he now thinks sales of Qsymia will peak at $1.2 billion a year, far below his previous estimate of $3.6 billion per year.

Read at CBS News
Read at Barron's Online
Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES